536747-52-1

Basic information

• Product Name: 1-(4-AMino-3-fluorophenyl)pyridin-2(1H)-one
• Synonyms: 1-(4-AMino-3-fluorophenyl)pyridin-2(1H)-one
• CAS NO: 536747-52-1
• Molecular Formula: C₁₁H₉FN₂O
• Molecular Weight: 204.2003632
• Mol File: 536747-52-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(4-AMino-3-fluorophenyl)pyridin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-AMino-3-fluorophenyl)pyridin-2(1H)-one(536747-52-1)
• EPA Substance Registry System: 1-(4-AMino-3-fluorophenyl)pyridin-2(1H)-one(536747-52-1)

Safety Data

• Hazardous Substances Data: 536747-52-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Amino-3-fluorophenyl)pyridin-2(1H)-one is used as a key intermediate for the synthesis of various drugs and pharmaceutical products. Its unique structure and properties make it a valuable compound in the development of new therapeutic agents.
Used in Drug Discovery and Development:
1-(4-Amino-3-fluorophenyl)pyridin-2(1H)-one is used as a starting material or building block for the creation of novel drug candidates. Its heterocyclic nature and functional groups allow for further chemical modifications and optimization to enhance the pharmacological properties of the resulting compounds.
Used in Research and Development:
1-(4-Amino-3-fluorophenyl)pyridin-2(1H)-one is used as a research tool to study the structure-activity relationships of various biologically active compounds. Its unique structure can provide insights into the design and synthesis of new drugs with improved efficacy and selectivity.
Further studies are needed to determine the specific uses and potential benefits of 1-(4-Amino-3-fluorophenyl)pyridin-2(1H)-one in the field of pharmaceuticals. Its versatility and unique structural features make it a promising candidate for various applications, including the development of new drugs and therapeutic agents.

Upstream product

• 142-08-5 2-Pyridone 
• 29632-74-4 2-fluro-4-iodoaniline 
• 148-24-3 8-quinolinol 
• 1036375-54-8 C₂₅H₂₁FN₂O 
• 675-20-7 piperidin-2-one 
• 896123-18-5 1-(3-fluoro-4-nitro-phenyl)-1H-pyridin-2-one 
• 142-08-5 2-hydroxypyridin 
• 367-24-8 4-bromo-2-fluoroaniline 

Downstream Products

• 886839-77-6 (1S,2S)-2-[2-Fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-4-methylene-cyclopentanecarboxylic acid ethyl ester 
• 865451-74-7 (3R,4R)-4-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenylcarbamoyl]pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 1036375-08-2 C₂₀H₂₀F₃N₃O₄ 
• 913744-77-1 5-chloro-thiophene-2-carboxylic acid {1-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylaminooxalyl]-pyrrolidin-3-yl}-amide 
• 913742-36-6 5-chloro-thiophene-2-carboxylic acid ((R)-1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-pyrrolidin-3-yl)-amide 
• 920305-71-1 7-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester 
• 920305-73-3 6-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid tert-butyl ester 
• 865528-39-8 C₂₃H₂₀ClFN₄O₃ 
• 1157846-22-4 C₂₇H₂₈FN₃O₅ 
• 1019995-72-2 3-{[(5-Chloro-thiophene-2-carbonyl)-amino]-methyl}-[1,2,4]oxadiazole-5-carboxylic acid [2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide 
• 1029963-73-2 (R)-5-methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide} 
• 1029963-90-3 N-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-2-methyl-acrylamide 
• 936828-28-3 1-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester 
• 936829-04-8 [2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-carbamic acid 4-nitro-phenyl ester 

Relevant articles and documents

SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5

Disclosed are compounds having structural formula I, and related salts and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases and conditions such as kidney disease, kidney failure, kidney stones, or polycystic kidney disease, using the compounds of formula (I), and related salts and pharmaceutical compositions.

SUBSTITUTED OXAZOLIDINONES AND USE THEREOF

The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

FACTOR XA INHIBITORS

The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat certain conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

PROCESSES FOR THE PREPARATION OF (3R, 4R) -N- (4 -CHLOROPHENYL) -1- (2, 2-DIFLUOROETHYL) -N' - [2-FLUORO-4- (2-OXO-1 (2H) -PYRIDINYL) PHENYL] -3, 4-PYRROLIDINEDICARBOXAMIDE

The invention is concerned with processes for the manufacture of pyrrolidine-3,4- dicarboxamide derivative of formula (I), and the intermediates useful for those processes.

(R) -5-METHYL-4, 5-DIHYDRO- PYRAZOLE-1, 5-DICARBOXYLIC ACID 1- [ ( 4 -CHLOROPHENYL) AMIDE 5-{ [2-FLUORO-4- (2-OXO-2H-PYRIDIN-1-YL) -PHENYL]AMIDE) AS A FACTOR XA INHIBITOR

(R) -5 -Methyl -4, 5-dihydro-pyrazole-1, 5 -dicarboxylic acid 1 - [ (4-chloro -phenyl) -amide] 5- {[2-f luoro-4- (2-oxo-2H-pyridin-1 -yl) -phenyl] -amide) pharmaceutical compositions, methods and methods of using the compound or pharmaceutical composition

FACTOR XA INHIBITORS

The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

TETRAHYDROISOQUINOLINES AS FACTOR XA INHIBITORS

The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

UREAS AS FACTOR XA INHIBITORS

The present invention is directed to compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

THIOUREAS AS FACTOR Xa INHIBITORS

The present invention is directed to compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

CRYSTALLINE FORMS OF A KNOWN PYRROLIDINE FACTOR XA INHIBITOR

Disclosed are crystalline forms A, B and C of 1 ,2-Pyrrolidinedicarboxamide, N1 -(4- chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1 (2H)-pyridinyl)phenyê]-4-methoxy-, (2R,4R)- (9Cl). These crystalline forms are characterized by their powder X-ray diffraction, solid-state NMR, as well as methods for the preparation and pharmaceutical compositions of the same which are useful for the treatment of acute, subacute, or chronic thrombotic disorders including treatment of venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, atherosclerosis, angina, primary and secondary deep vein thrombosis, thromboembolism associated with cardiovascular disease, including, but not limited to, acute coronary syndrome, atrial fibrillation, cardiac valve replacement and deep vein thrombosis. The crystalline forms of the present invention are also useful for the treatment of cancer, sepsis and diabetes.